Cargando…

2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019

BACKGROUND: to evaluate circulation of drug resistance mutations (DRMs), sub-types (ST) and Herpesviruses replication among subjects recently diagnosed as HIV infected (pts) in Veneto (Italy), over 16 years, comparing previously reported trends with the most recent one, updated to 2019. METHODS: on...

Descripción completa

Detalles Bibliográficos
Autores principales: Basso, Monica, Parisatto, Beatrice, Stagni, Camilla, Zago, Daniela, Pozzetto, Irene, Scaggiante, Renzo, Cruciani, Mario, Ferretto, Roberto, Manfrin, Vinicio, Francavilla, Ermenegildo, Panese, Sandro, Sarmati, Loredana, Dal Bello, Federico, Andreoni, Massimo, Palù, Giorgio, Parisi, Saverio G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809653/
http://dx.doi.org/10.1093/ofid/ofz360.2184
_version_ 1783462043616018432
author Basso, Monica
Parisatto, Beatrice
Stagni, Camilla
Zago, Daniela
Pozzetto, Irene
Scaggiante, Renzo
Cruciani, Mario
Ferretto, Roberto
Manfrin, Vinicio
Francavilla, Ermenegildo
Panese, Sandro
Sarmati, Loredana
Dal Bello, Federico
Andreoni, Massimo
Palù, Giorgio
Parisi, Saverio G
author_facet Basso, Monica
Parisatto, Beatrice
Stagni, Camilla
Zago, Daniela
Pozzetto, Irene
Scaggiante, Renzo
Cruciani, Mario
Ferretto, Roberto
Manfrin, Vinicio
Francavilla, Ermenegildo
Panese, Sandro
Sarmati, Loredana
Dal Bello, Federico
Andreoni, Massimo
Palù, Giorgio
Parisi, Saverio G
author_sort Basso, Monica
collection PubMed
description BACKGROUND: to evaluate circulation of drug resistance mutations (DRMs), sub-types (ST) and Herpesviruses replication among subjects recently diagnosed as HIV infected (pts) in Veneto (Italy), over 16 years, comparing previously reported trends with the most recent one, updated to 2019. METHODS: on plasma from 2919 patients diagnosed from July 2004 to April 2019, protease (PR), reverse transcriptase (RT) and recently Integrase (In) were analyzed for DRMs, susceptibility profile (Stanford db) and ST. Potential low-level resistances were excluded. CMV-DNA and EBV-DNA were evaluated by in-house Real-Time-PCR in PBMCs. RESULTS: in 5 periods (2004/06, 07/09, 10/12, 13/16, 17–19) 334, 796, 752, 750 and 287 patients were recruited; non-B-ST were 21.9, 29.3, 33, 32.7 and 48.1% (33.5% Italians in 17–19), respectively. A significant increase of non-B-ST (P < 0.0001 for trend) and of the percentage of Italians with non-B-strains (P = 0.029) were observed. Resistance to PR or to multiple classes declined but not to non-nucleoside RT inhibitors (NNRTI) (Fig 1). E138A alone, not included in the previous evaluations, increased from 2.3 to 1.8, to 3.2, to 3.6, to 4.7% in 2017-19. No primary TDRM to In-Inhibitors (InIn) were found in 469 B-ST-Pts enrolled in 2014–19; 16% had major TDRM for RT/PI. Among 231 non-B patients, 12,5% with other TDRMs, only a 143C and a 66I were found. Accessory InIn-TDRMs were detected (Figures 2 and 3). Nevertheless, from 2009 to 2019 in Veneto 114 InIn-failed and potentially transmitters patients with In-DRMs were found. In 2017–19 17,3% of patients had CMV-DNA in PBMCs, with a median CD4 of 55 (8%), HIV-RNA 247251 cps/mL and EBV-DNA of 811 cps/106 PBMCs (3% were neg); Patients CMV-DNA-negative (82,7%) had median CD4 of 334 (18,9%), HIV-RNA 47770 cps/mL and a significantly lower EBV-DNA of 194 cps/106 PBMCs (15% were neg): differences between immuvirological variables were significant. CONCLUSION: An increase of non-B strains and a slight increase of TDRMs among B-ST were observed. The persistent circulation of NNRTI-DRMs, the shortage of major In-TDRMs but a circulation of many In-polymorphisms have implications on the screening at baseline and on the selection of the first-line HAART. Many patients with lower CD4 and higher HIV replication has an incomplete control of co-infecting herpesviruses, which contribute to immunoactivation. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809653
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68096532019-10-28 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019 Basso, Monica Parisatto, Beatrice Stagni, Camilla Zago, Daniela Pozzetto, Irene Scaggiante, Renzo Cruciani, Mario Ferretto, Roberto Manfrin, Vinicio Francavilla, Ermenegildo Panese, Sandro Sarmati, Loredana Dal Bello, Federico Andreoni, Massimo Palù, Giorgio Parisi, Saverio G Open Forum Infect Dis Abstracts BACKGROUND: to evaluate circulation of drug resistance mutations (DRMs), sub-types (ST) and Herpesviruses replication among subjects recently diagnosed as HIV infected (pts) in Veneto (Italy), over 16 years, comparing previously reported trends with the most recent one, updated to 2019. METHODS: on plasma from 2919 patients diagnosed from July 2004 to April 2019, protease (PR), reverse transcriptase (RT) and recently Integrase (In) were analyzed for DRMs, susceptibility profile (Stanford db) and ST. Potential low-level resistances were excluded. CMV-DNA and EBV-DNA were evaluated by in-house Real-Time-PCR in PBMCs. RESULTS: in 5 periods (2004/06, 07/09, 10/12, 13/16, 17–19) 334, 796, 752, 750 and 287 patients were recruited; non-B-ST were 21.9, 29.3, 33, 32.7 and 48.1% (33.5% Italians in 17–19), respectively. A significant increase of non-B-ST (P < 0.0001 for trend) and of the percentage of Italians with non-B-strains (P = 0.029) were observed. Resistance to PR or to multiple classes declined but not to non-nucleoside RT inhibitors (NNRTI) (Fig 1). E138A alone, not included in the previous evaluations, increased from 2.3 to 1.8, to 3.2, to 3.6, to 4.7% in 2017-19. No primary TDRM to In-Inhibitors (InIn) were found in 469 B-ST-Pts enrolled in 2014–19; 16% had major TDRM for RT/PI. Among 231 non-B patients, 12,5% with other TDRMs, only a 143C and a 66I were found. Accessory InIn-TDRMs were detected (Figures 2 and 3). Nevertheless, from 2009 to 2019 in Veneto 114 InIn-failed and potentially transmitters patients with In-DRMs were found. In 2017–19 17,3% of patients had CMV-DNA in PBMCs, with a median CD4 of 55 (8%), HIV-RNA 247251 cps/mL and EBV-DNA of 811 cps/106 PBMCs (3% were neg); Patients CMV-DNA-negative (82,7%) had median CD4 of 334 (18,9%), HIV-RNA 47770 cps/mL and a significantly lower EBV-DNA of 194 cps/106 PBMCs (15% were neg): differences between immuvirological variables were significant. CONCLUSION: An increase of non-B strains and a slight increase of TDRMs among B-ST were observed. The persistent circulation of NNRTI-DRMs, the shortage of major In-TDRMs but a circulation of many In-polymorphisms have implications on the screening at baseline and on the selection of the first-line HAART. Many patients with lower CD4 and higher HIV replication has an incomplete control of co-infecting herpesviruses, which contribute to immunoactivation. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809653/ http://dx.doi.org/10.1093/ofid/ofz360.2184 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Basso, Monica
Parisatto, Beatrice
Stagni, Camilla
Zago, Daniela
Pozzetto, Irene
Scaggiante, Renzo
Cruciani, Mario
Ferretto, Roberto
Manfrin, Vinicio
Francavilla, Ermenegildo
Panese, Sandro
Sarmati, Loredana
Dal Bello, Federico
Andreoni, Massimo
Palù, Giorgio
Parisi, Saverio G
2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title_full 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title_fullStr 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title_full_unstemmed 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title_short 2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
title_sort 2506. trends of transmitted resistance mutations to four drug classes, hiv-subtypes and herpesviruses replication among subjects recently diagnosed as hiv infected over 2004–2019
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809653/
http://dx.doi.org/10.1093/ofid/ofz360.2184
work_keys_str_mv AT bassomonica 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT parisattobeatrice 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT stagnicamilla 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT zagodaniela 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT pozzettoirene 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT scaggianterenzo 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT crucianimario 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT ferrettoroberto 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT manfrinvinicio 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT francavillaermenegildo 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT panesesandro 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT sarmatiloredana 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT dalbellofederico 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT andreonimassimo 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT palugiorgio 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019
AT parisisaveriog 2506trendsoftransmittedresistancemutationstofourdrugclasseshivsubtypesandherpesvirusesreplicationamongsubjectsrecentlydiagnosedashivinfectedover20042019